Visceral Pain Market: Global Industry Analysis and Forecast (2023-2029)

Visceral Pain Market size was valued at US$ 12.84 Bn. in 2022 and the total revenue is expected to grow at a CAGR of 5.2% through 2023 to 2029, reaching nearly US$ 18.32 Bn.
Visceral Pain Market Overview:
When internal organs and tissues are harmed or wounded, pain is felt. The stimulation of nociceptors in the thoracic, pelvic, or abdominal viscera causes visceral pain. Visceral pain can be caused by injuries to the gallbladder, intestines, bladder, or kidneys. Medications such as pain relievers, spasmolytics, and antidepressants are used to treat symptoms. Chronic Prostatitis, Interstitial Cystitis, Crohn’s Disease, and Ulcerative Colitis are the indications types of the visceral pain. Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies are the types of the distribution channel of the visceral pain market.To know about the Research Methodology :- Request Free Sample Report
Visceral Pain Market Dynamics:
The visceral pain market is expected to be driven by pharmaceutical companies' increased focus on research and development, as well as government initiatives, during the forecast period 2023-2029. The market is expected to grow significantly during the forecast period as a result of greater collaboration among pharmaceutical companies.

The growth in interest among scientists and researchers in examining pain originating from internal organs has corresponded with a greater understanding of the importance of visceral pain in patients. Various types of medications on the market have been used off-label for pain management in recent years, despite their analgesic properties. The global market for innovative targeted drug therapy is expected to be continue to grow as a result of this factor. The global geriatric population is expected to reach 2 billion by 2050, contributing significantly to the visceral pain market growth during the forecast period 2023-2029.

During the forecast period, the recent launch and approval of new medications in North America, Europe, and Japan is expected to increase demand for visceral pain treatment. MEDI2070 interleukin-23 monoclonal antibody is being developed by AstraZeneca and Allergan to treat ulcerative colitis and Crohn's disease. The MEDI2070 is currently being tested in phase IIb for moderate to severe Crohn's disease and phase II for ulcerative colitis. For Crohn's disease and ulcerative colitis, Pfizer's PF-00547659 and Celgene's Ozanimod are in phase II and phase III clinical trials, respectively.

High treatment costs are expected to hinder the market's growth. Costs are expected to fall as a result of a range of factors including higher manufacturing scales, significant drug research and development, and government grants and subsidies. The market's progress has been impeded in recent years by a lack of public awareness.
Segment Analysis:
Based on the Drug Type, the market is segmented into Pain Modifiers, Analgesics, and Others. Analgesics segment is expected to hold the largest market shares of xx% by 2029. The segment growth is expected to drive by widely available products paired with over-the-counter sales during the forecast period. Analgesics include narcotics and nonsteroidal anti-inflammatory medications (NSAIDs).

Commonly prescribed as the first line of treatment for common inflammation are NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). Because they primarily suppress the manufacture of prostaglandins, which are formed in response to cell injury, NSAIDs are usually referred to as steroids. NSAID complications affect 100,000 patients each year, according to The American Journal of Medicine, with 20,000 deaths.

Under the businesses' recently announced interim exclusive supply and distribution agreement, Lannett Company, Inc. will launch Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, an opioid pain reliever, in August 2021. Baudax Bio was founded as a new pharmaceutical firm with the goal of developing non-opioid analgesic medicines that are both effective and safe.

Based on the Indication, the market is segmented into Chronic Prostatitis, Interstitial Cystitis, Crohn’s Disease, and Ulcerative Colitis. Ulcerative Colitis and Crohn’s Disease segments are expected to grow rapidly at a CAGR of xx% and xx% during the forecast period 2023-2029. In the recent several decades, there has been a significant increase in the prevalence and incidence of IBDs, which is expected to continue during the forecast period. According to IBD Support Australia Incorporated, inflammatory bowel disease affects roughly 61,000 people in Australia, with Crohn's disease affecting 28,000 people and ulcerative colitis affecting 33,000.

Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Retail Pharmacies segment is expected to grow rapidly at a CAGR of xx% during the forecast period 2023-2029. This is due to favourable demographic considerations and a shift in the epidemiological landscape. The Retail Pharmacies segment is expected to be driven by the inclusion of several drugs under the OTC category and a desire for self-medication.
Regional Insights:
North America region is expected to dominate the Visceral Pain market during the forecast period 2023-2029.

North America region is expected to hold the largest market shares of xx% by 2029. This is due to the growth in government programmes and increased awareness of visceral pain treatment. In addition, the market in North America is being driven by a boom in investment in research and development by numerous pharmaceutical companies. The key companies with medications in the visceral pain therapy pipeline are Neomed Management AS, Arena Pharmaceuticals, Inc., and Anavex Life Sciences Corp. Increased disease incidence is another important driver boosting the market in the region. Every year, around 70,000 new instances of inflammatory bowel disease (IBD) are diagnosed in the United States. There could be as many as 80,000 youngsters with IBD in the country.

Asia Pacific is expected to grow rapidly at a CAGR of xx% during the forecast period 2023-2029.

During the forecast period, the market in Asia Pacific is expected to be driven by the adoption of innovative treatment approaches, pipeline pharmaceuticals, and increased government partnerships with commercial businesses and clinical laboratories. According to NCBI statistics from 2022, the incidence of ulcerative colitis in Asia was over 1 per 100,000 individuals, whereas Crohn's disease was slightly lower, at around 0.5 per 100,000 people.

The objective of the report is to present a comprehensive analysis of the Global Visceral Pain Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The reports also help in understanding the Global Visceral Pain Market dynamic, structure by analyzing the market segments and project the Global Visceral Pain Market size. Clear representation of competitive analysis of key players by Drug Type Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Visceral Pain Market make the report investor’s guide.
Visceral Pain Market Scope: Inquire before buying



Visceral Pain Market


Base Year
2022
Forecast Period
2023-2029


Historical Data
CAGR
Market Size in 2022
Market Size in 2029


2018 to 2022
5.2%
US$ 12.84 Bn
US$ 18.32 Bn


Segments Covered


by Drug Type
Pain Modifiers
Analgesics
Others
by Indication
Chronic Prostatitis
Interstitial Cystitis
Crohn’s Disease
Ulcerative Colitis
by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies


Regions Covered


North America
United States
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Sweden
Austria
Rest of Europe
Asia Pacific
China
S Korea
Japan
India
Australia
Indonesia
Malaysia
Vietnam
Taiwan
Bangladesh
Pakistan
Rest of APAC
Middle East and Africa
South Africa
GCC
Egypt
Nigeria
Rest of ME&A
South America
Brazil
Argentina
Rest of South America



Visceral Pain Market Key Players
1. Pfizer Inc.
2. Allergan Inc.
3. Johnson & Johnson Services Inc.
4. Abbvie
5. Takeda Pharmaceutical Company Limited
6. AstraZeneca
7. Bayer AG
8. Mallinckrodt Pharmaceuticals
9. Addex Therapeutics
10. Astellas Pharma Inc.
11. Novartis AG
12. Sanofi
13. GlaxoSmithKline plc
14. Boehringer Ingelheim International GmbH
15. Zyla Life Sciences
16. Horizon Therapeutics plc

Frequently Asked Questions:

1] What segments are covered in Visceral Pain Market report?
Ans. The segments covered in Visceral Pain Market report are based on Drug Type, Indication, and Distribution Channel.

2] Which region is expected to hold the highest share in the Visceral Pain Market?
Ans. North America is expected to hold the highest share in the Visceral Pain Market.

3] Who are the top key players in the Visceral Pain Market?
Ans. Pfizer Inc., Allergan Inc., Johnson & Johnson Services Inc., Abbvie, and Takeda Pharmaceutical Company Limited are the top key players in the Visceral Pain Market.

4] Which segment holds the largest market share in the Visceral Pain market by 2029?
Ans. Analgesics segment hold the largest market share in the Visceral Pain market by 2029.

5] What is the market size of the Visceral Pain market by 2029?
Ans. The market size of the Visceral Pain market is expected to reach US $ 18.32 Bn. by 2029.

6] What was the market size of the Visceral Pain market in 2022?
Ans. The market size of the Visceral Pain market was worth US $ 12.84 Bn. in 2022.